Abstract
We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Busulfan / administration & dosage
-
Combined Modality Therapy
-
Female
-
Follow-Up Studies
-
Graft vs Host Disease / prevention & control
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / therapy*
-
Primary Myelofibrosis / pathology
-
Primary Myelofibrosis / therapy*
-
Remission Induction
-
Survival Rate
-
Transplantation Conditioning*
-
Transplantation, Homologous
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Alemtuzumab
-
Vidarabine
-
Busulfan
-
fludarabine